

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,650	01/22/2005	Oleg Iliich Epshtein		7546
70098 7590 04/14/2008 Houston Eliseeva LLP - RU 4 Militia Drive - suite 4			EXAMINER	
			SZPERKA, MICHAEL EDWARD	
Lexington, M/	A 02421		ART UNIT	PAPER NUMBER
			1644	
			NOTIFICATION DATE	DELIVERY MODE
			04/14/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

maria@patentbar.com achristophoroff@z-c.ru



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

INVENTOR / ATTORNEY DOCKET NO.
EEXAMINATION
N ET AL.

Houston Eliseeva LLP - RU 4 Militia Drive - suite 4 Lexington, MA 02421

EXAMINER Michael Szperka				
1644	20080402A			

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Upon review of the response and amendments received January 9, 2008 the following matter was observed: Applicant has added new claim 6 and as amended paragraph 12 to recite biological sequence information. Applicant is reminded that the requirements of applications which contain sequence disclosures that include neuleotide and/or amino acid sequences are set forth in 37 CFR 1.821-1.825. Applicant is further reminded that if the instant application does not have an appropriate SEQ ID NO: for each disclosed sequence, then Applicant must comply with the Sequence Rules as set forth in 37 CFR 1.821-1.825. The instant specification and claims do not recite the sequence by SEQ ID number and no sequence listing has been provided. As such, it appears that the instant application does not satisfy the requirements set forth in 37 CFR 1.821-1.825. Appropriate correction to comply with the rules is required.

Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is 571-272-2934. The examiner can normally be reached on M-F 8:00-4:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara can be reached on 571-272-0878. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-1917 (full-free).

/Michael Szperka, Ph.D./ Primary Examiner Art Unit: 1644